IL324469A - נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהם - Google Patents

נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהם

Info

Publication number
IL324469A
IL324469A IL324469A IL32446925A IL324469A IL 324469 A IL324469 A IL 324469A IL 324469 A IL324469 A IL 324469A IL 32446925 A IL32446925 A IL 32446925A IL 324469 A IL324469 A IL 324469A
Authority
IL
Israel
Prior art keywords
bispecific antibody
amino acid
seq
antibody
acid sequence
Prior art date
Application number
IL324469A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL324469A publication Critical patent/IL324469A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL324469A 2023-05-09 2024-05-08 נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהם IL324469A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363501036P 2023-05-09 2023-05-09
PCT/EP2024/062700 WO2024231440A1 (en) 2023-05-09 2024-05-08 Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof

Publications (1)

Publication Number Publication Date
IL324469A true IL324469A (he) 2026-01-01

Family

ID=91082227

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324469A IL324469A (he) 2023-05-09 2024-05-08 נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהם

Country Status (13)

Country Link
EP (1) EP4709750A1 (he)
JP (1) JP2026518603A (he)
KR (1) KR20260008784A (he)
CN (2) CN121057745A (he)
AR (1) AR132641A1 (he)
AU (1) AU2024269156A1 (he)
CL (1) CL2025003427A1 (he)
CO (1) CO2025016972A2 (he)
CR (1) CR20250521A (he)
IL (1) IL324469A (he)
MX (1) MX2025013179A (he)
TW (1) TW202509059A (he)
WO (1) WO2024231440A1 (he)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
SG11201809778TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
MX2021000889A (es) * 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.

Also Published As

Publication number Publication date
CL2025003427A1 (es) 2026-02-13
CO2025016972A2 (es) 2025-12-19
AR132641A1 (es) 2025-07-16
CN122427291A (zh) 2026-07-21
JP2026518603A (ja) 2026-06-09
KR20260008784A (ko) 2026-01-16
TW202509059A (zh) 2025-03-01
MX2025013179A (es) 2025-12-01
AU2024269156A1 (en) 2026-01-08
EP4709750A1 (en) 2026-03-18
CR20250521A (es) 2026-01-14
CN121057745A (zh) 2025-12-02
WO2024231440A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
US20260015420A1 (en) Cd47 binding agents
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
US11773176B2 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
JP2025520413A (ja) FcRn結合分子及び使用方法
US12528868B2 (en) CD1a antibodies and uses thereof
TW202346358A (zh) 經工程改造之cd200r抗體及其用途
US20240254239A1 (en) Depletion of activated hepatic stellate cells (hscs) and uses thereof
US20250122288A1 (en) Fcrn binding molecules and methods of use
AU2017292752A1 (en) Antibodies with low immunogenicity and uses thereof
US20250326852A1 (en) Materials and methods for targeting regulatory t cells for enhancing immune surveillance
WO2025140212A1 (en) Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
CN112384535A (zh) 用于治疗慢性荨麻疹的方法和组合物
US20230227545A1 (en) Materials and methods of il-1beta binding proteins
TW202509059A (zh) 具有經修飾Fc區之雙特異性抗假單胞菌抗體及其使用方法
CN117203230A (zh) 特异性识别c5a的抗体及其应用
WO2024160261A1 (en) Anti-lilrb1 and/or anti-lilrb2 antibodies and uses thereof
KR20260064755A (ko) 항-acvr2b 항체 및 이의 용도